ArticleFrontiers in immunology2026
Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1-3a follicular lymphoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) exhibits substantial clinical heterogeneity, and progression of disease within 24 months (POD24) represents a critical adverse clinical endpoint. Traditional prognostic models rely predominantly on tumor-related parameters and overlook systemic immune-inflammatory status. The newly established FLIPI24 index emphasizes peripheral blood markers but lacks immune-related indicators. Here, we investigated the prognostic value of the baseline systemic immune-inflammation index (SII) and developed a novel FLIPI-SII model to improve risk stratification in patients with grade 1-3a FL. A total of 628 patients were used for model training/internal validation, and 187 R-CHOP-treated patients for external validation. High SII (>580) was significantly correlated with inferior overall survival (OS) and progression-free survival (PFS), and was identified as an independent prognostic risk factor in multivariate regression analysis. The predictive efficacy of SII remained stable in patients receiving rituximab-based immunochemotherapy. We further constructed a 6-item FLIPI-SII scoring system, which categorized patients into four distinct risk subgroups and exerted powerful predictive performance for POD24. The model effectively predicted both PFS and OS in our cohort and was validated in two external centers. The FLIPI-SII model presented higher C-index values than conventional FLIPI, FLIPI2, and PRIMPI for both OS and PFS prediction. In conclusion, baseline SII acts as a stable, non-invasive, and independent prognostic biomarker for grade 1-3a FL. The newly developed FLIPI-SII model greatly improves the prediction of POD24 and long-term survival, providing a reliable immune-associated tool for individualized clinical risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.